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0.7%, p¼0.9976).
Conclusion: This sub-analysis of the ORBIT II study demonstrates that males and
females treated with orbital atherectomy for severely calciﬁed coronary arteries
(generally regarded as high-risk revascularization) demonstrate similar 30-day out-
comes. In the context of the larger study, one can presume that the novel coronary
Orbital Atherectomy System is a safe and effective adjunctive therapy for severely









Feasibility of the Use of the Tryton™ Dedicated Bifurcation Stent via the Transradial
Route - A Single Centre Experience
Ashish Shah, Muezz Uddin, Shantu Bundhoo, Richard Anderson, Tim Kinnaird
University Hospital of Wales, Cardiff, Cardiff, United Kingdom
Background: The use of the Transradial access (TR) for the treatment of Coronary
Bifurcation Lesions (CBL) with Percutaneous Coronary Intervention (PCI) can be
limited where a two stent strategy is required as larger sheath and guide catheters are
required to facilitate stent delivery. With the development of newer dedicated bifur-
cation stents, there is an increasing trend of these stents to be adopted in PCI centres
to treat CBL’s. We report our experience of the use of the Tryton dedicated side
branch bifurcation stent at our default TR centre where 90% of all PCI are carried out
via the TR.
Methods: This was a prospective study of all patients who were found suitable to
undergo PCI to CBL’s using the Tryton stent between September 2009 and June
2013. Data on patient demographics and procedure characteristics was collected from
the local hospital database.
Results: 36 patients (Male 69.4%, age 68.1 years) underwent PCI using the
19mm long Tryton bifurcation stent. Most of the CBL’s treated were located in
the LAD/Branch (52.8%), followed by the Circumﬂex/Branch (27.8%), Left
main stem/Branch (13.9%), RCA/Branch (2.7%) and LIMA graft (2.7%).
Tryton stents dimensions (Side branch/Main branch diameters) deployed were
(2.5/2.5mm - 11.1%; 2.5/3.0mm - 25%; 2.5/3.5mm - 47.2%; 3.0/3.5mm - 8.3%
and 3.5/4.0mm - 8.3%). 91.6% of cases were carried out via 6F guide catheters
with the remaining cases carried out via the 7F. Mean contrast volume, radiation
dose and ﬂuoroscopy times were 306 mls, 98.8 Gy/cm2 and 28.2 minutes
respectively. 94.4% of all cases were successfully carried out via the TR route with
remaining cases switching to the transfemoral route to successfully complete the
procedure.
Conclusions: When treating CBL’s, a wide range of Tryton dedicated side branch
stents can be safely and effectively deployed via the TR route using 6F/7F Guide
catheter systems. This can avoid the use of the transfemoral route and its associated
potential vascular complications.CABG
CRT-132
Under-Utilization of Statins and Aspirin Following Coronary Artery Bypass Graft
Surgery
Kevin Curl, Bryan LeBude, Nicholas Ruggiero, David Fischman, Andrew Rose,
Sulay Patel, David Ogilby, Paul Walinsky, Babu Jasti, Michael Savage
Thomas Jefferson University Hospital, Philadelphia, PA
Background: Coronary artery bypass graft (CABG) surgery is commonly performed
to treat ischemic heart disease, but long term beneﬁts are limited by patency of
saphenous vein grafts. Both statin medications and aspirin hold class I indications for
all post-CABG patients and should be continued indeﬁnitely unless contraindication
exists. Unfortunately, there is limited data regarding long-term usage of these medi-
cations. We assessed utilization rates among post-CABG patients without docu-
mented contraindication.
Methods: A retrospective analysis of post-CABG patients presenting to the Thomas
Jefferson University cardiac catheterization laboratory for a catheterization procedure at
least 3 years after surgery was performed. Inpatient and outpatient records were
reviewed to assess prescribing patterns of these medications, as well as other pertinent
clinical and laboratory data.
Results: The study population consisted of 381 consecutive patients who presented
on average 11  6 years from the time of CABG. Mean age of our study population
was 69  11 years with 78% male. The most common indications for catheterization
were unstable angina (36%), non-STEMI (22%), and an abnormal stress test (15%).
Only 67% of patients were being prescribed a statin, while 75% were prescribed
aspirin. Only 52% were prescribed both at the time of catheterization. Three percent
had a documented intolerance to statin therapy. Patients prescribed a statin had a
signiﬁcantly lower mean LDL (87 vs. 106 [p<0.01]) and total cholesterol values (151
vs. 162 [p<0.01]). Thirty ﬁve percent of patients had LDL  100. Only 43% of
saphenous vein grafts among the patients not on statin medications remained patent
an average of 11 years post-CABG surgery.
Conclusions: Long-term statin and aspirin use following CABG surgery remains
suboptimal despite clear guideline recommendations and clinical trial evidence of their
effectiveness. Coordinated efforts are needed to improve long-term medication usage
in this subset of high risk patients.
Cardiovascular Pharmacology
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Omeprazole Use is Associated with Increased Cardiovascular Complications in Asian
Patients on Aspirin and Clopidogrel After Percutaneous Coronary Intervention
Min Sen Yew, Poh Shuan Daniel Yeo, Jau Lueng Paul Ong, Lijuan Mira Shen,
Hee Hwa Ho, Fahim Haider Jafary, Yau Wei Ooi, Kwok Kong Jason Loh,
Ko Beng Julian Tan, Chee Guan David Foo
Tan Tock Seng Hospital, Singapore, Singapore
Background: Dual anti-platelet therapy (DAPT) with Aspirin and a Thienopyridine-
derivative P2Y12 Inhibitor (commonly Clopidogrel) is mandatory after Percutaneous
Coronary Intervention (PCI). H2 receptor antagonists (H2RA) or Proton Pump
Inhibitors (PPI) are prescribed to reduce gastrointestinal bleeding risk.








YClopidogrel is a prodrug that requires activation by CYP2C19 and other isoenzymes of
the cytochrome P450 system. Carriers of a loss-of-function CYP2C19 allele have lower
levels of the active metabolite, resulting in reduced platelet inhibition and a potentially
higher rate of adverse cardiovascular events. As PPI are competitive inhibitors of
CYP2C19, coadministration with Clopidogrel can further reduce the latter’s antiplatelet
activity.
The COGENT randomised trial which enrolled predominantly white Caucasian
males did not demonstrate any adverse interaction between Clopidogrel and Omep-
razole use. However, this interaction may be signiﬁcant in Asian patients as up to 55%
of Asians carry a loss-of-function CYP2C19 allele as compared to 30% of Caucasians.
We hypothesize that Asian patients taking both Clopidogrel and the PPI Omeprazole
are at higher risk of adverse cardiovascular events post-PCI.
Methods: This retrospective cohort study in a 1300-bed tertiary hospital in Singapore
included all patients from 1st January to 31st December 2011 who had PCI and
received either Omeprazole or a H2RA, together with 12 months of Aspirin and
Clopidogrel. Prescription and outcome data were retrieved from electronic medical
records. The primary outcome was the incidence of cardiovascular complications
within 12 months of the initial PCI. Cardiovascular complication is deﬁned as car-
diovascular death, non-fatal myocardial infarction, need for urgent target vessel
revascularisation and ischemic stroke.
Results: We identiﬁed 933 patients, of which 614 patients met the criteria for in-
clusion. The primary outcome occurred in 27 of 296 patients (9.1%) from the
Omeprazole group and 13 of 318 patients (4.1%) from the H2RA group (p ¼ 0.014).
The difference remained statistically signiﬁcant after adjustment for baseline differ-
ences in cardiovascular risk factors in both groups (p ¼ 0.042).
Conclusions: Using Omeprazole rather than a H2RA was associated with a signif-
icantly greater incidence of cardiovascular complications in Asian patients on Clopi-
dogrel after PCI. Larger studies are required to further evaluate this observation.
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Metformin Does Not Adversely Impact Outcome Following Percutaneous Coronary
Intervention in Patients with Diabetes Mellitus
Michael J. Lipinski, Lakshmana Pendyala, Rebecca Torguson, Fang Chen,
Lowell F. Satler, William O. Suddath, Augusto D. Pichard, Ron Waksman
MedStar Heart Institute, Washington, VA
Background: The use of metformin in patients with non-insulin-dependent diabetes
mellitus (NIDDM) has been associated with improved cardiovascular outcomes. How-
ever, recent studies raise concern that use of metformin may inhibit endothelialization
following limus-eluting stent (LES) placement and increase the risk of stent thrombosis.
Therefore, we set out to study the impact of metformin on stent thrombosis and major
adverse cardiovascular events in patients that received drug-eluting stents (DES).
Methods: We evaluated consecutive patient with NIDDM discharged on oral anti-
hyperglycemic agents that underwent DES placement at our institution from 2003
through 2012. We assessed stent thrombosis, major adverse cardiovascular events
(MACE), target lesion revascularization, myocardial infarction, and all-cause mortality
at one year and analyzed the impact of metformin use and stent type on these outcomes.
Results: We included 1,201 patients with a mean age of 66  10 years, 64.1% were
male, 63.5% had ACS, 74.8% received LES, 25.2% received paclitaxel-eluting stents
(PES), and 55% were taking Metformin. There was no difference in stent thrombosis,
regardless of stent type or metformin use. Whether or not patients received LES or PES
did not signiﬁcantly impact MACE (Figure 1A) or all-cause mortality (Figure 1B).
Patients takingmetformin had a signiﬁcant reduction inMACE (p¼0.002) and all-cause
mortality (p¼0.002) compared with patients not taking metformin (Figure 1C and
Figure 1D, respectively). However, multivariate analysis demonstrated that stent type and
metformin use were not signiﬁcantly associated with MACE or all-cause mortality.
Conclusion: In patients with NIDDM, the use of metformin following placement of
DES did not increase the risk of stent thrombosis and MACE, regardless of the type
of stent placed.Chronic Total Occlusion
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Rationale of the Decision-Making of Treatment in Chronic Total Occlusion Lesions in a
University Hospital
Luis R. Alvarez-Contreras, Victoria Martin-Yuste, Salvatore Brugaletta,
Yajaziel Azpeitia-Hernandez, Alejandro Santos, Manel Sabate
Hospital Clinic de Barcelona, Barcelona, Spain
Background: The presence of a chronic total occlusion (CTO) in up to 30% of
routine angiograms emphasizes the importance to select an optimal treatment strategy
effectiveness of its treatment and its implication in future clinical events.
Objective:We assessed the rationale for decision-making in treatment of CTO at our
institution.
Methods: From June 2010 to December 2012 we evaluated all consecutive patients in
our catheterization laboratory in which at least one CTO was diagnosed. Data were
prospectively collected on treatment decisions (medical vs. surgery vs. percutaneous
coronary intervention <PCI>), PCI indications and subsequent cardiac events
through time.
Results: 711 patients with at least one CTO in the basal coronary angiogram were
included. Two groups were made according to programmed to PCI (PPCI)¼189
patients and non-programed to PCI (NPPCI)¼522 patients. There was a statistical
difference among basal characteristics in patients PPCI vs. NPPCI with less acute
myocardial infarction (AMI) 16(13,6%) vs. 81(15,5%) p¼0.016; less involvement of
3-vessel disease 56(29,6%) vs. 224 (42,9%) p¼0.002; and less presence of coronary
left-main disease 12 (6,4%) vs. 72 (13,8%) p¼0.007. There was also a difference
between age (62,610.4 years vs. 68,310.7 years; p¼<0.0001); ejection fraction
(EF) (47,113,8% vs. 44,913,9;p¼0.017%) and creatinine clearance (70,8 28,6
ml/min vs. 62 23,1, ml/min; p¼<0.001). The multivariate analysis demonstrated
that the following variables in predicting no PCI as ﬁrst step approach in CTO
lesions: AMI, number of diseased vessels, left main lesion and age. There was a
trend to be treated by PCI as ﬁrst step approach in patients with positive ischemia
by a stress test.
Conclusion: In a large all comer CTO lesion population, in a University hospital; the
ﬁrst step approach of revascularization is dictated by clinical factors as age, comorbidity
(EF and creatinine clearance), AMI; anatomical factors such as left-main disease and
3-vessel disease. On the other hand, at our institution the choice of PCI as ﬁrst step
